Table 1.

Tumor-specific antibody therapies.

Target	Antibodies	Anti-tumor effect	Reseaon of limited efficacy	Improving the therapeutic efficacy
CD20	rituximab	complement-dependent cytotoxicity (CDC); direct target cell apoptosis; antibody-dependent phagocytosis; ADCC	the loss of CD20 antigen causing the increase of antigen-loss cells resistant to NK cell-mediated ADCC and reducing the efficacy as a result; poor affinity of rituximab to FcγRIIIa; increase the release of inhibitory substances suppressing the immune reaction through weakening NK cell-mediated ADCC; the impaired NK cell activity in the CLL patients
	Obinutuzumab			glycoengineering
	Ofatumumab
	Ublituximab
CD19	inebilizumab (MEDI-551).			afucosylation: increase the binding affinity of mAbs to FcγRIIIa
				Fc-engineering
CD16	BiKEs(a single-chain variable fragment (scFv) recognizing CD16 + a scFv recognizing tumor antigens)	transferring signals as immunological synapses and to induce cytotoxicity
	TriKEs	increasing the possibility of identifying tumor cells in the case of one antigen missing and reduces immunological evasion